Clinical Trial

A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a multicenter, randomized, double-blind, placebo-parallel-controlled phase II clinical trial to evaluate the efficacy and safety of HRS-1780 compared with placebo in participants with primary aldosteronism. The study plans to enroll 60 participants.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-01
Trial Details
NCT Number NCT07470983
Lead Sponsor Shandong Suncadia Medicine Co., Ltd.
Conditions Primary Aldosteronism
Enrollment 60 participants
Start Date 2026-04-23
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-04-30